INSERM U996, DHU Hepatinov, Univ Paris-Sud, Université Paris-Saclay, 92140 Clamart, France; Institut Paris-Sud d'Innovation Thérapeutique (IPSIT), IFR141, Faculté de Pharmacie, Univ Paris-Sud, Université Paris-Saclay, Châtenay-Malabry, France.
Division of Gastroenterology, Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, ON M5T 3L9, Canada; Department of Medicine, University of Toronto, ON M5S 1A8, Canada.
J Hepatol. 2017 Apr;66(4):806-815. doi: 10.1016/j.jhep.2016.11.008. Epub 2016 Nov 25.
BACKGROUND & AIMS: Alcoholic liver disease (ALD) is a leading cause of liver failure and mortality. In humans, severe alcoholic hepatitis is associated with key changes to intestinal microbiota (IM), which influences individual sensitivity to develop advanced ALD. We used the different susceptibility to ALD observed in two distinct animal facilities to test the efficiency of two complementary strategies (fecal microbiota transplantation and prebiotic treatment) to reverse dysbiosis and prevent ALD.
Mice were fed alcohol in two distinct animal facilities with a Lieber DeCarli diet. Fecal microbiota transplantation was performed with fresh feces from alcohol-resistant donor mice to alcohol-sensitive receiver mice three times a week. Another group of mice received pectin during the entire alcohol consumption period.
Ethanol induced steatosis and liver inflammation, which were associated with disruption of gut homeostasis, in alcohol-sensitive, but not alcohol resistant mice. IM analysis showed that the proportion of Bacteroides was specifically lower in alcohol-sensitive mice (p<0.05). Principal coordinate analysis showed that the IM of sensitive and resistant mice clustered differently. We targeted IM using two different strategies to prevent alcohol-induced liver lesions: (1) pectin treatment which induced major modifications of the IM, (2) fecal microbiota transplantation which resulted in an IM very close to that of resistant donor mice in the sensitive recipient mice. Both methods prevented steatosis, liver inflammation, and restored gut homeostasis.
Manipulation of IM can prevent alcohol-induced liver injury. The IM should be considered as a new therapeutic target in ALD.
Sensitivity to alcoholic liver disease (ALD) is driven by intestinal microbiota in alcohol fed mice. Treatment of mice with alcohol-induced liver lesions by fecal transplant from alcohol fed mice resistant to ALD or with prebiotic (pectin) prevents ALD. These findings open new possibilities for treatment of human ALD through intestinal microbiota manipulation.
酒精性肝病(ALD)是肝衰竭和死亡的主要原因。在人类中,严重的酒精性肝炎与肠道微生物群(IM)的关键变化有关,这会影响个体对进展性 ALD 的敏感性。我们利用两个不同的动物设施中观察到的对 ALD 的不同易感性,来测试两种互补策略(粪便微生物群移植和益生元治疗)逆转失调和预防 ALD 的效率。
使用 Lieber DeCarli 饮食,用酒精在两个不同的动物设施中喂养小鼠。每周三次,用来自抗酒精供体小鼠的新鲜粪便进行粪便微生物群移植,将其转移到酒精敏感的受体小鼠中。另一组小鼠在整个酒精摄入期间接受果胶。
乙醇诱导的脂肪变性和肝炎症与酒精敏感但非酒精抗性小鼠的肠道内稳态破坏有关。IM 分析显示,酒精敏感小鼠的拟杆菌比例特别低(p<0.05)。主坐标分析显示,敏感和抗性小鼠的 IM 聚类不同。我们使用两种不同的策略针对 IM 来预防酒精引起的肝损伤:(1)果胶治疗,其引起 IM 的主要变化,(2)粪便微生物群移植,其导致敏感受体小鼠中的 IM 非常接近抗性供体小鼠的 IM。这两种方法均能预防脂肪变性、肝炎症和恢复肠道内稳态。
IM 的操纵可以预防酒精引起的肝损伤。IM 应被视为 ALD 的新治疗靶点。
在给予酒精的小鼠中,对酒精性肝病(ALD)的敏感性是由肠道微生物群驱动的。用来自对 ALD 有抵抗力的酒精喂养小鼠的粪便移植或用益生元(果胶)治疗有酒精诱导的肝损伤的小鼠可预防 ALD。这些发现为通过肠道微生物群操纵治疗人类 ALD 开辟了新的可能性。